Tradestie Institutional Equity Comparison Engine
ACAD vs AQB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ACAD Overall Edge
ACAD Captures Institutional Edge (4โ0 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ACAD trades at 16.9x Forward P/E with 10.2% operating margin (+22.8% YoY revenue) versus AQB at N/M Forward P/E and 0.0% operating margin (-93.5% YoY). In options structure, ACAD sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro) against AQB sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
ACAD
ACAD 16.9x vs AQB N/M Fwd P/E
Growth & Margin Winner
ACAD
Op Margin 10.2% vs 0.0% ยท YoY +22.8% vs -93.5%
Momentum & Technical Winner
ACAD
1Y -23.7% vs -23.6% ยท 52W Pos 16% vs 11%
Options & Structure Winner
ACAD
BREAKDOWN (9th %ile IV) vs BREAKDOWN (N/A IV)
ACAD
NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$18.32
-1.87% 1D
Market Cap
$3.2B
1M Return
-7.47%
1Y Return
-23.73%
Forward P/E
16.9x
Unified AI Score
47.9 / 100
HOLD
Tech 48.0
Fund 57.0
Flow 65.0
Mom 60.0
AQB
NASDAQ
AquaBounty Technologies, Inc.
Fishing, Hunting And Trapping
$0.82
+2.01% 1D
Market Cap
$9.7M
1M Return
-21.37%
1Y Return
-23.57%
Forward P/E
N/M
Unified AI Score
44.6 / 100
HOLD
Tech 33.0
Fund 49.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ACAD -23.73%
AQB -23.57%
Spread: +0.16 pp (AQB Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ACAD Revenue | AQB Revenue | ACAD Op. Margin | AQB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $220M | $0M | -110.6% | -12264.6% | ACAD |
| FY2019 | $340M | $0M | -72.7% | -7057.3% | ACAD |
| FY2020 | $440M | $0M | -64.9% | -12727.1% | ACAD |
| FY2021 | $480M | $0M | -35.2% | -1883.0% | ACAD |
| FY2022 | $520M | $0M | -43.2% | -711.6% | ACAD |
| FY2023 | $730M | $0M | -10.1% | -552.9% | ACAD |
| FY2024 | $960M | N/A | 24.1% | N/A | ACAD |
| FY2025 | $1.07B | N/A | 9.8% | N/A | ACAD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACAD | AQB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.2B | $9.7M | Larger Scale | ACAD |
| Trailing P/E Ratio Valuation | 8.8x | N/M | Lower Multiple | ACAD |
| Forward P/E Ratio Valuation | 16.9x | N/M | Lower Multiple | ACAD |
| Revenue Growth (YoY) Growth | +22.8% | -93.5% | Higher Growth | ACAD |
| Operating Margin (TTM) Profitability | 10.2% | 0.0% | Higher Margin | ACAD |
| Net Profit Margin Profitability | 30.1% | 0.0% | Higher Margin | ACAD |
| Return on Equity (ROE) Capital Efficiency | 31.4% | -68.9% | Higher ROE | ACAD |
| 52-Week Range Position Momentum | 16% ($16โ$31) | 11% ($1โ$2) | Stronger Trend | ACAD |
| Beta / 30D Volatility Risk Regime | 0.16ฮฒ ยท 90% Vol | 0.93ฮฒ ยท 117% Vol | Lower Realized Risk | ACAD |
| Unified Institutional Score Composite Signal | 47.9 / 100 (HOLD) | 44.6 / 100 (HOLD) | Higher Composite | ACAD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ACAD vs AQB Buy Guide
ACAD
BREAKDOWN
59d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
9th %ile
IV Regime
Compressed (<25th %ile)
AQB
BREAKDOWN
69d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ACAD nor AQB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.